Utilizing Isolate Of Tissue Or Organ As Binding Agent Patents (Class 436/503)
-
Patent number: 6858397Abstract: Antibodies are disclosed which specifically bind to native PrPSc in situ. Preferred antibodies bind only to the native PrPSc of a particular species e.g., human, cow, sheep, pig, etc. Particularly preferred antibodies bind specifically to a particular isoform of human PrPSc. Preferred antibodies of the invention are (1) produced by phage display methodology, (2) bind specifically to native PrPSc, (3) neutralizes the infectivity of prions, (4) bind to PrPSc in situ and (5) bind 50% or more of PrPSc in a liquid flowable sample. Antibodies of the invention can be bound to a substrate and used to assay a sample (which has any PrPc denatured via proteinase K) for the presence of PrPSc of a specific species which PrPSc is associated with disease. Antibodies which specifically bind to human PrPSc can be labeled and injected carrying out an in vivo diagnostic test to determine if the human is infected with prions associated with disease.Type: GrantFiled: May 9, 2003Date of Patent: February 22, 2005Assignees: The Regents of the University of California, The Scripps Research InstituteInventors: Stanley B. Prusiner, R. Anthony Williamson, Dennis R. Burton
-
Patent number: 6855560Abstract: DNAs encoding the human histamine H3 receptor have been cloned and characterized. The recombinant protein is capable of forming biologically active histamine H3 receptor protein. The cDNA's have been expressed in recombinant host cells which produce active recombinant protein. The recombinant protein is also purified from the recombinant host cells. In addition, the recombinant host cells are utilized to establish a method for identifying modulators of the receptor activity, and receptor modulators are identified.Type: GrantFiled: August 21, 2000Date of Patent: February 15, 2005Assignee: Ortho McNeil Pharmaceutical, Inc.Inventors: Timothy W. Lovenberg, Mark Erlander, Arne Huvar, Jayashree Pyati
-
Patent number: 6846638Abstract: Methods, compositions, kits, and apparatus are provided wherein the aminoacyl-tRNA synthetase system is used to analyze amino acids. The method allows very small devices for quantitative or semi-quantitative analysis of the amino acids in samples or in sequential or complete proteolytic digestions. The methods can be readily applied to the detection and/or quantitation of one or more primary amino acids by using cognate aminoacyl-tRNA synthetase and cognate tRNA. The basis of the method is that each of the 20 synthetases and/or a tRNA specific for a different amino acid is separated spatially or differentially labeled. The reactions catalyzed by all 20 synthetases may be monitored simultaneously, or nearly simultaneously, or in parallel. Each separately positioned synthetase or tRNA will signal its cognate amino acid. The synthetase reactions can be monitored using continuous spectroscopic assays.Type: GrantFiled: August 9, 2001Date of Patent: January 25, 2005Assignee: NanoBioDynamics, Inc.Inventor: Edward Shipwash
-
Patent number: 6844164Abstract: An antibody biding specifically to rat's acrosome reacted sperm is produced and hybridomas (FARS-91 and FARS-92 strains) capable of stably proliferating are obtained by fusing mouse spleen cells having a high antibody titer against rat's acrosome reacted sperm with mouse-origin myeloma cells and screening fused cells reacting strongly with rat's acrosome reacted sperm. From these hybridomas, monoclonal antibodies selectively binding to rat's acrosome reacted sperm can be obtained. Thus, a diagnostic method for evaluating fertility of rat's spermatozoa is presented.Type: GrantFiled: October 23, 2000Date of Patent: January 18, 2005Assignee: FUSO Pharmaceutical Industries, Ltd.Inventors: Yoshihiro Kuwahara, Michinori Hasegawa, Kiyotsugu Isaka, Hiromasa Araki
-
Patent number: 6835549Abstract: This invention pertains to an in vitro immunoassay method for diagnosing human gastric intestinal metaplasia which comprises the steps of (a) contacting a gastric tissue sample of a subject suspected of having human gastric intestinal metaplasia cells with the monoclonal antibody DAS-1, or a fragment thereof, which monoclonal antibody is produced by the hybridoma deposited under ATCC accession number HB 9397 and which reacts with human gastric intestinal metaplasia antigen; and (b) detecting immunoreactivity between the gastric tissue and the monoclonal antibody, such immunoreactivity indicating a positive diagnosis of human gastric intestinal metaplasia.Type: GrantFiled: February 24, 2000Date of Patent: December 28, 2004Assignee: University of Medicine & Dentistry of New JerseyInventor: Kiron M. Das
-
Patent number: 6815214Abstract: The synthesis of novel diketopiperazines, their use in inhibiting cellular events such as those involving NFK-&agr;, NFK-&bgr; and in the treatment of inflammation events, a combinatorial library of diverse diketopiperazines and process for their synthesis as a library and as individual compounds. In particular novel diketopiperazines are disclosed including their synthesis and use in cellular events such as activation of the transcription factor, nuclear factor, TNF-&agr;, TNF-&bgr; and also apoptosis.Type: GrantFiled: December 28, 2001Date of Patent: November 9, 2004Assignee: Celltech R & D, Inc.Inventors: Jim P. Boyce, J. Jeffry Howbert, John C. Tabone
-
Patent number: 6811988Abstract: The present invention provides methods and compositions for the diagnosis of Alzheimer's disease. In particular, the present invention provides modified beta-amyloid peptides, antibodies that specifically bind to the modified beta-amyloid peptides, and methods for using these compositions in the diagnosis of Alzheimer's disease, as well as methods to monitor treatment and/or disease progression of Alzheimer's disease in patients. The present invention also provides compositions and methods useful in research involving amyloid precursor protein (APP) metabolism and Alzheimer's disease.Type: GrantFiled: October 21, 2002Date of Patent: November 2, 2004Inventors: Mario Chojkier, Martina Buck
-
Patent number: 6800436Abstract: With respect to a range of 1.5 Mbp and more in the chromosome 19p13.3 region containing Peutz-Jeghers gene, a continuous cosmid contig is constructed and a restriction map is prepared. Next, genes mapped with this region are searched by using EST database and the locations of these genes are accurately determined. Based on the evaluation of biological data, etc., several highly likely candidates for Peutz-Jeghers genes are specified from the genes thus found. After successively analyzing variations in these genes in DNAs of patients with Peutz-Jeghers syndrome, it is found that one of these genes, i.e., “LKB1” has been specifically varied in these patients. Thus, the diseases caused by the variation in the LKB1 gene can be diagnosed and treated by using the LKB1 gene, primers and probes based on its base sequence, LKB1 protein, an antibody biding to this protein, etc.Type: GrantFiled: May 25, 2000Date of Patent: October 5, 2004Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Dieter E. Jenne, Jun-ichi Nezu
-
Patent number: 6773892Abstract: Methods for detecting schizophrenia or related neuropsychiatric disorders based on modifications of the contribution of the D4 receptor to phospholipid methylation levels are described herein. Individuals with schizophrenia or related neuropsychiatric disorders have a deficiency in phospholipid methylation activity compared with normal individuals. Methods for screening therapeutic processes or agents for use in treatment of schizophrenia or related neuropsychiatric disorders are also described.Type: GrantFiled: April 14, 2000Date of Patent: August 10, 2004Assignee: Northeastern UniversityInventor: Richard C. Deth
-
Patent number: 6743595Abstract: The invention relates to a method and a kit for the diagnosis of endometriosis using blood and endometrial leukocyte markers or a combination thereof. The marker is a surface antigen from endometrial or blood leukocytes.Type: GrantFiled: January 24, 2000Date of Patent: June 1, 2004Assignee: Metriogene Biosciences Inc.Inventors: Diane Gosselin, Danièle Gagné, Patrice Hugo, Pierre Miron
-
Patent number: 6730482Abstract: This invention is directed towards a method for obtaining nucleic acid ligands against target proteins without directly purifying the target proteins. The method used in the invention is called SELEX, which is an acronym for Systematic Evolution of Ligands by EXponential enrichment. The nucleic acid ligands of the invention are useful as diagnostic and therapeutic agents for diseases in which the targets proteins play a causative role.Type: GrantFiled: March 12, 2002Date of Patent: May 4, 2004Assignee: SomaLogic, Inc.Inventors: Larry Gold, Dominic A. Zichi, Jonathan Drew Smith
-
Patent number: 6723518Abstract: An isolated chemokine is disclosed. The isolated chemokine is expressed preferentially in breast tissue or can be detected in breast milk. It includes from about 100 to about 132 amino acids, has a deduced molecular weight of from about 10 to about 16 kDa, and has a deduced isoionic point of from about pH 10.1 to about pH 10.7. Antibodies and binding portions thereof recognizing the subject chemokine and peptides which include the antigenic portions of the subject chemokines are described. DNA molecules which encode the subject chemokines as well as nucleic acid molecules which, under stringent conditions, hybridize to nucleic acid molecules encoding the subject chemokines or to a complement thereof are also disclosed.Type: GrantFiled: April 13, 2001Date of Patent: April 20, 2004Assignee: Codon Diagnostics, LLCInventors: Lawrence D. Papsidero, Lyn M. Dyster, Jana M. Frustaci
-
Patent number: 6720192Abstract: A method for assaying an analyte in a sample. The method comprising the steps of a) contacting the sample with material comprising a receptor which is present in a liposome and which liposome comprises a detectable functionality, said contact occurring under conditions resulting in binding of the receptor to analyte if present before or concomitant with step b, wherein step b) consists of contacting the sample with an immobilised ligand for the receptor said contact occurring under conditions resulting in binding of the receptor to the ligand, with steps a and b being followed by c) separating the resulting immobilised ligand-receptor fraction and the receptor fraction present in solution and d) assaying the detectable functionality of the receptor in a fraction from step c) in a manner known per se for its detection.Type: GrantFiled: May 9, 2001Date of Patent: April 13, 2004Assignee: Merska B.V.Inventors: Gerhard Theodoor Viel, Kornelis Ensing
-
Patent number: 6709832Abstract: The present invention relates to a method for the early diagnosis of carcinomas and their preliminary stages, which comprises determining the overexpression of a cell cycle regulatory protein in a body sample. The invention also provides a kit usable for this purpose.Type: GrantFiled: August 3, 2001Date of Patent: March 23, 2004Assignees: Deutsches KrebsforschungszentrumInventors: Magnus Von Knebel Doeberitz, Dimitry Spitkovsky
-
Patent number: 6686146Abstract: The present invention encompasses methods for determining the likelihood that benign hyperplastic breast tissue or normal breast tissue adjacent to carcinoma tissue will become malignant. The methods comprise substantially isolating the tissue; and determining loss of heterozygosity (LOH) at chromosome 3p24 in the tissue. LOH at chromosome 3p24 is a prognostic indicator that the tissue may become malignant.Type: GrantFiled: October 18, 1996Date of Patent: February 3, 2004Assignee: California Pacific Medical CenterInventors: Guoren Deng, You Lu, Helene S. Smith
-
Patent number: 6680203Abstract: The present invention relates to methods for high information content (HIC) analysis or screening of complex biological systems using Fourier transform mass spectrometry (FTMS). The present methods are useful for analyzing complex biological mixtures containing both high molecular weight molecules (e.g., polynucleotides, proteins, polysaccharides) and low molecular weight molecules (e.g., oligonucleotides, peptides, lipids, oligosaccharides, steroid hormones, catabolic and metabolic intermediates) permit the elucidation of molecular differences between complex biological samples, and permit the identification of biologically active molecules (e.g. therapeutically active drugs, etc.).Type: GrantFiled: December 12, 2000Date of Patent: January 20, 2004Assignee: Esperion Therapeutics, Inc.Inventors: Jean-Louis H. Dasseux, Roger S. Newton, Thomas J. Rea, Charles L. Bisgaier, Michael E. Pape
-
Patent number: 6677125Abstract: An assay method is disclosed which isolates and detects the presence of a disease related conformation of a protein (e.g., PrPSc) present in a sample also containing the non-disease related conformation of the protein (e.g., PrPC). The sample is treated (e.g., contacted with protease) in a manner which hydrolyzes the disease related conformation and not the non-disease related conformation. The treated sample is contacted with a binding partner (e.g., a labeled antibody which binds PrPSc) and the occurrence of binding provides and indication that PrPSc is present. Alternatively the PrPSc of the treated sample is denatured (e.g., contacted with guanadine) or unfolded. The unfolded PrPSc is contacted with a binding partner and the occurrence of binding indicates the presence of PrPSc in the sample.Type: GrantFiled: January 14, 2002Date of Patent: January 13, 2004Assignee: The Regents of the University of CaliforniaInventors: Stanley B. Prusiner, Jiri G. Safar
-
Patent number: 6664378Abstract: An antibody that binds to a specific urogenital carcinoma tumor liberated protein (TLP) epitope, wherein the TLP comprises GlyProProGluValGlnAsnAlaAsn, is described. Also described are kits comprising the antibody, and methods of identifying TLP, and methods for diagnosing urogenital carcinoma.Type: GrantFiled: September 14, 2000Date of Patent: December 16, 2003Assignee: Unihart CorporationInventor: Giulio Tarro
-
Patent number: 6660530Abstract: A method for labeling &bgr;-amyloid plaques and neurofibrillary tangles in vivo and in vitro, comprises contacting a compound of formula (I): with mammalian tissue.Type: GrantFiled: June 26, 2001Date of Patent: December 9, 2003Assignee: The Regents of the University of CaliforniaInventors: Jorge R. Barrio, Andrej Petric, Nagichettiar Satyamurthy, Gary W. Small, Gregory M. Cole, Sung-Cheng Huang
-
Patent number: 6649368Abstract: Compositions and methods are described for enhancing the immunohistochemical staining of tissue samples. Compositions include a single solution, which includes at least one surfactant, adapted to remove an embedding medium of a tissue sample, rehydrate the tissue sample, and enhance the immunohistochemical staining of the tissue in relation to immunohistochemical staining of unreacted tissue. Methods include heating the tissue sample with the composition to enhance the immunohistochemical staining of the tissue.Type: GrantFiled: February 29, 2000Date of Patent: November 18, 2003Assignee: Cell Marque CorporationInventors: Nora Betyousef Aghassi, Kim Franceschini, Paul John Ardi
-
Patent number: 6645774Abstract: This invention provides methods of modifying feeding behavior, including increasing or decreasing food consumption, e.g., in connection with treating obesity, bulimia or anorexia. These methods involve administration of compounds that are selective agonists or antagonists for the Y5 receptor. One such compound has the structure: In addition, this invention provides an isolated nucleic acid molecule encoding a Y5 receptor, an isolated Y5 receptor protein, vectors comprising an isolated nucleic acid molecule encoding a Y5 receptor, cells comprising such vectors, antibodies directed to the Y5 receptor, nucleic acid probes useful for detecting nucleic acid encoding Y5 receptors, antisense oligonucleotides complementary to any unique sequences of a nucleic acid molecule which encodes a Y5 receptor, and nonhuman transgenic animals which express DNA encoding a normal or a mutant Y5 receptor.Type: GrantFiled: November 23, 1999Date of Patent: November 11, 2003Assignee: Synaptic Pharmaceutical CorporationInventors: Christophe P. G. Gerald, Richard L. Weinshank, Mary W. Walker, Theresa Branchek
-
Patent number: 6645734Abstract: A monoclonal antibody binding selectively to neurosin obtained from hybridomas, in particular, strain 2B2-6 and strain S2E5 showing stable proliferation ability. These hydridomas are obtained by fusing mouse spleen cells having a high antibody titer against neurosin with mouse-derived myeloma cells, screening fused cells being highly reactive with neurosin, and thus producing an antibody binding specifically to neurosin. By using this antibody, various diseases in which neurosin participates can be diagnosed.Type: GrantFiled: December 21, 2000Date of Patent: November 11, 2003Assignee: Fuso Pharmaceutical Industries, Ltd.Inventors: Katsuya Kominami, Akira Okui, Shinichi Mitsui, Nozomi Yamaguchi
-
Patent number: 6638727Abstract: The invention is to methods for identifying asymptomatic patients who have a likelihood of benefiting from administration of an estrogen activity modulator for risk reduction or therapeutic treatment of breast cancer, methods for reducing risk or therapeutically treating these asymptomatic patients, and methods for monitoring the treatments.Type: GrantFiled: May 17, 1999Date of Patent: October 28, 2003Assignee: Cytyc Health CorporationInventors: David T. Hung, Susan Love
-
Patent number: 6638771Abstract: A composition and method for the diagnosis of autoimmune hepatitis. The composition, which contains SLA antigens detects soluble liver antigen (SLA) auto-antibodies, which occur in sera of patients suffering from chronic hepatitis.Type: GrantFiled: September 25, 2000Date of Patent: October 28, 2003Inventor: Ansgar W. Lohse
-
Patent number: 6630310Abstract: A preparation containing a receptor for underivatized, aqueous soluble &bgr;(1-3)-glucan is disclosed, along with characterization of the receptor for underivatized, aqueous soluble &bgr;(1-3)-glucan. Also described are assays for identifying agents which alter the effect of underivatized, aqueous soluble &bgr;(1-3)-glucan on activation of signal transduction pathways and agents identified thereby, as well as assays for assessing the specificity of carbohydrate:glycolipid interactions.Type: GrantFiled: October 30, 1998Date of Patent: October 7, 2003Assignee: Biopolymer Engineering Pharmaceutical, Inc.Inventors: Eric Wakshull, William M. Mackin, Janet Zimmerman
-
Patent number: 6620590Abstract: A method for diagnosis of pre-eclampsia is disclosed, which comprises measuring the hormone inhibin A in a biological sample such as maternal serum. The method allows non-invasive, early diagnosis and can be used to predict the onset of secondary symptoms.Type: GrantFiled: April 25, 2001Date of Patent: September 16, 2003Assignees: Isis Innovation Limited, The University of Reading, Oxford Brookes UniversityInventors: Nigel Patrick Groome, Philip Gerald Knight, William Leigh Ledger, Christopher Willard George Redman, Shanthi Muttukrishna
-
Patent number: 6613537Abstract: The present invention is drawn to pyrrolopyridinium derivatives having a new structural skeleton, preferably containing an intramolecular hemiacetal, which is clearly different from any known Advanced Glycation Endproduct (AGE) and which, when present in an organism, has a bioactivity unlike the conventional AGE. The present invention provides pyrrolopyridinium derivatives and pharmaceutically acceptable salts thereof, an antibody prepared from said derivatives as a hapten, a method for the diagnosis of diabetes, diabetic complications, renal failure, dialysis-related complications, amyloidosis, aging, diseases accompanied by aging, etc. using said derivatives or an antibody prepared therefrom and a method for evaluating effectiveness of pharmaceuticals used to treat diabetes, diabetes-related diseases, dialysis-related complications, aging, diseases accompanied by aging, etc.Type: GrantFiled: February 28, 2001Date of Patent: September 2, 2003Assignee: Nippon Zoki Pharmaceutical Co., Ltd.Inventors: Ko Nakamura, Seikoh Horiuchi, Norie Araki
-
Patent number: 6613526Abstract: This invention discloses high-affinity oligonucleotide ligands to complex tissue targets, specifically nucleic acid ligands having the ability to bind to complex tissue targets, and the methods for obtaining such ligands. Tissue targets comprise cells, subcellular components, aggregates or cells, collections of cells, and higher ordered structures. Specifically, nucleic acid ligands to red blood cells ghosts, endothelia of the blood brain and CSF-blood barriers, glioblastomas, and lymphomas are described.Type: GrantFiled: February 14, 2002Date of Patent: September 2, 2003Assignee: Gilead Sciences, Inc.Inventors: Joseph S. Heilig, Larry Gold
-
Patent number: 6610484Abstract: Methods and systems for identifying material from a breast duct using one or more markers that can be identified in ductal fluid retrieved from the breast are provided.Type: GrantFiled: July 26, 2000Date of Patent: August 26, 2003Assignee: Cytyc Health CorporationInventor: David T. Hung
-
Patent number: 6593095Abstract: The present invention relates to toxins that specifically bind to GPI anchored proteins. More specifically, the present invention encompasses the uses of such toxins to detect the presence or absence of GPI anchored proteins. In one embodiment the present invention can be used to detect the presence of paroxysmal nocturnal hemoglobinuria.Type: GrantFiled: July 14, 2000Date of Patent: July 15, 2003Assignees: University of Victoria Innovation and Development Corporation, Johns Hopkins UniversityInventors: J. Thomas Buckley, Robert A. Brodsky
-
Patent number: 6589746Abstract: Patients having several neurological diseases have been shown to have elevated levels of axonally-derived proteins (i.e. tau and neurofilament proteins) in cerebrospinal fluid (CSF) and in brain tissue. Three monoclonal antibodies (MAbs) recognizing CSF tau proteins were developed. The MAbs were found to label a ladder of 30 kD to 50 kD tau proteins in CSF from patients with disease states producing axonal damage such as head trauma or CNS tumor but not in CSF from controls. High levels of tau protein in CSF were shown to be diagnostic of axonal degeneration in head trauma. An ELISA assay was developed with these MAbs to aid in the diagnosis of patients with axonal damage.Type: GrantFiled: October 23, 2000Date of Patent: July 8, 2003Assignee: University of CincinnatiInventor: Frank P. Zemlan
-
Patent number: 6586192Abstract: The invention relates to a methods of obtaining and expanding a purified population of long-term repopulating hematopoietic stem cells. The invention also relates to the uses of a purified population of long-term repopulating hematopoietic stem cells.Type: GrantFiled: May 28, 1999Date of Patent: July 1, 2003Assignees: Thomas Jefferson University, Instituto Superiore di SanitaInventors: Cesare Peschle, Benedikt L. Ziegler
-
Patent number: 6582928Abstract: The invention provides heterobifunctional cross-linking reagents and methods of using the cross-linking reagents. The cross-linking reagents of the invention combine a nucleophilic hydrazide residue with an electrophilic maleimide residue allowing coupling of aldehydes to free thiols. In the methods of the invention, human immunodeficiency virus (HIV) infected cells can be detected using conjugates that include CD4 molecules conjugated to detectable markers via the disclosed cross-linking reagents.Type: GrantFiled: March 2, 2000Date of Patent: June 24, 2003Assignee: Genentech, Inc.Inventors: Avi J. Ashkenazi, Steven M. Chamow, Timothy P. Kogan
-
Patent number: 6562341Abstract: Antibodies are disclosed which specifically bind to native PrPSc in situ. Preferred antibodies bind only to the native PrPSc of a particular species e.g., human, cow, sheep, pig, etc. Particularly preferred antibodies bind specifically to a particular isoform of human PrPSc. Preferred antibodies of the invention are (1) produced by phage display methodology, (2) bind specifically to native PrPSc, (3) neutralizes the infectivity of prions, (4) bind to PrPSc in situ and (5) bind 50% or more of PrPSc in a liquid flowable sample. Antibodies of the invention can be bound to a substrate and used to assay a sample (which has any PrPc denatured via proteinase K) for the presence of PrPSc of a specific species which PrPSc is associated with disease. Antibodies which specifically bind to human PrPSc can be labeled and injected carrying out an in vivo diagnostic test to determine if the human is infected with prions associated with disease.Type: GrantFiled: August 30, 2001Date of Patent: May 13, 2003Assignees: The Regents of the University of California, The Scripps Research InstituteInventors: Stanley B. Prusiner, R. Anthony Williamson, Dennis R. Burton
-
Patent number: 6555656Abstract: A prion-physiological structure and associated method of formation. A provided abnormal prion has a transforming power over a normal prion to convert the abnornal prion into defective prion that mimics the abnormal prion. A linker molecule is then bonded to the abnormal prion, wherein a polymer that is covalently attached to the linker molecule facilitates formation of a polymerized abnormal prion that does not have the transforming power over the normal prion.Type: GrantFiled: May 18, 2001Date of Patent: April 29, 2003Assignee: Albany Medical CollegeInventor: Mark D. Scott
-
Publication number: 20030072752Abstract: A method of modulating cell proliferation or apoptosis comprising modulating psoriastatin activity.Type: ApplicationFiled: October 16, 1996Publication date: April 17, 2003Applicant: General Hospital Corporation, a Massachusetts corporationInventors: TOSHIHIKO HIBINO, TADAHITO TAKAHASHI, PETER C. BACIU, PAUL F. GOETINCK
-
Patent number: 6548306Abstract: The full amino acid and DNA sequences of placental protein 13 (PP13) are disclosed. Also described are various PP13 derived peptide fragments, and a recombinant method for the production of PP13. PP13 may be used in a screening and a diagnostic method for pregnancy-related complications.Type: GrantFiled: January 31, 2001Date of Patent: April 15, 2003Assignee: Diagnostic Technologies Ltd.Inventors: Arie Admon, Yoav Paltieli, Ronit Slotky, Silvia Mandel
-
Patent number: 6541206Abstract: A method of testing sperm quality including obtaining a sample of sperm to be tested; detecting and measuring the testis-specific HspA2 chaperone protein (or, the chaperone protein homologues to HspA2) in human and animal sperm; and determining a sperm quality parameter based upon the chaperone protein, wherein an increased amount of the chaperone protein species indicates a higher sperm quality. The chaperone protein is detected and measured either by binding one or more antibodies specific to the sperm chaperone protein to the sperm and measuring the antibody content or measuring ATP bound to the sperm chaperone protein. In the case of the latter method, the chaperone protein may be detected and measured by measuring ATP bound to the sperm chaperone protein, and such measuring is by chaperone protein-bound and CK-B generated ATP measurement, or by bioluminescence of the chaperone protein bound-ATP.Type: GrantFiled: June 19, 2000Date of Patent: April 1, 2003Inventor: Gabor B. Huszar
-
Patent number: 6537765Abstract: Assays for the identification of compounds useful for the modulation of body weight, metabolic rate, or feeding behavior are disclosed. Such compounds are useful for the treatment body weight disorders, e.g., obesity and cachexia. The methods involve cell-free and cell-based assays that identify compounds which alter ligand binding to and/or alter the activity of GPR10, a G protein-coupled receptor, optionally followed by an in vivo assay of the effect of the compound on feeding behavior, body weight, or metabolic rate.Type: GrantFiled: March 6, 2001Date of Patent: March 25, 2003Assignee: Millennium Pharmaceuticals, Inc.Inventors: Alain Stricker-Kongra, Wei Gu
-
Patent number: 6531277Abstract: A method and kit of diagnosing endometriosis in a female patient suspected of having endometriosis is disclosed. The method includes obtaining a sample from the patient. The sample is analyzed to detect the presence of ENDO -I glycoprotein or its mRNA in the sample compared to non-endometriosis controls who do not express ENDO-I. The protein is characterized by (i) a molecular weight of 40,000 to 55,000 as determined by two-dimensional SDS-PAGE polyacrylamide gel electrophoresis; (ii) having an isoelectric point of 4.0 to 5.5; and (iii) being synthesized and secreted specifically by stromal cells of endometriotic tissue origin; and (iv) in humans having a cDNA as set forth in SEQ ID No:1. The present invention further discloses a cDNA for human ENDO-I (SEQ ID No:1) and antibody directed against ENDO-I.Type: GrantFiled: March 19, 1998Date of Patent: March 11, 2003Assignee: The Curators of the University of MissouriInventor: Kathy L. Timms
-
Patent number: 6531512Abstract: A method of treating cancer in a patient deficient in p53 tumor suppression gene is described herein by administering to a patient a therapeutically effective amount if a polyamine such as DENSPM in combination with an anticancer agent. Also described is a method of selecting patients for cancer treatment with a polyamine, for example, DENSPM.Type: GrantFiled: March 12, 2001Date of Patent: March 11, 2003Assignee: Health Research Inc.Inventors: Debora L. Kramer, Carl W. Porter
-
Patent number: 6492128Abstract: A drug screening assay for identifying compounds for their potential effects on the long chain fatty acid dependant intracellular membrane anchorage sites of lipoproteins. Membranes-anchoring-target are incubated in the presence of the compound to be tested and the proportion of the target that is released by the compound is detected and quantitated. The benchmark for this assay are the prenylated proteins such as the farnesylated and palmitoylated oncogenic ras trigger proteins which are displaced from their anchorage at the intracellular plasma membrane by derivatives of Farnesyl Thiosalicylic Acid (FTS). The assay is adaptable to flexibly assay a large variety of anchored targets using a wide range of labeling and detection techniques in test wells, tissue culture, and in animals as injected cells or transgenic, thereby directly addressing a wide range of pharmacologically relevant needs.Type: GrantFiled: June 7, 2000Date of Patent: December 10, 2002Assignee: Ramot University Authority for Applied Research & Industrial Development, Ltd.Inventors: Roni Haklai, Ariella Paz, Yoel Kloog
-
Patent number: 6472143Abstract: The present invention provides a novel complex of hK2 and PI-6 and methods of using the novel complex and its constituents. The novel complexes of hK2 and PI-6 of the present invention and the PI-6 exist at an elevated level in prostate cancer tissues. PI-6 also exists at an elevated level in other types of cancer cells. Therefore, the hK2-PI6 complexes and PI-6 of the present invention may be used as a serum marker for detecting cancers, particularly prostate cancer. They may also be used as an immunohistological marker to detect prostate cancer tissues. In accordance with the present invention, the hK2-PI6 complexes of the present invention may be detected in patient tissue samples by immunohistochemical and/or in patient fluid samples by in vitro immunoassay procedures. Diagnostic methods for detecting the existence of prostate cancer is also provided.Type: GrantFiled: September 22, 2000Date of Patent: October 29, 2002Assignee: Hyrbritech IncorporatedInventors: Stephen D. Mikolajczyk, Mohammad S. Saedi
-
Patent number: 6458550Abstract: Ovarian autoimmunity is implicated in ovarian dysfunction associated with premature ovarian failure (POF) and unexplained infertility. A rapid, quantitative, and inexpensive method of clinical diagnosis of ovarian autoimmunity is provided. Diagnosis is provided by detection of autoantibodies that react with an ovarian antigen, 17 -alpha-hydroxylase. This diagnostic method is applicable to ovarian autoimmunity unassociated with polyglandular disease.Type: GrantFiled: January 7, 2000Date of Patent: October 1, 2002Assignee: Rush-Presbyterian-St. Luke's Medical CenterInventor: Judith L. Luborsky
-
Patent number: 6451541Abstract: The present invention relates to methods for the detection or isolation of prion proteins by use of chaperones specifically binding to said proteins. The invention further relates to a method for in vitro diagnosis of a transmissible spongiform encephalopathy and to pharmaceutical compositions, preferably for the prevention or treatment of said disease.Type: GrantFiled: November 12, 1998Date of Patent: September 17, 2002Inventors: Ernst-Ludwig Winnacker, Stefan Weiss, Frank Edenhofer, Roman Rieger
-
Patent number: 6444477Abstract: The present invention relates to the finding that receptors for the neurotransmitter 5-HT of the 5-HT2B class are located on the human colon, and that their activation potentiates neuronally-mediated responses, and are thus causative in the abnormal motility and pain associated with IBS. The invention provides a method of treatment of IBS which comprises providing to a patient in need of treatment an effective amount of a 5HT2B receptor antagonist which acts on 5HT2B receptors located in the colon of said patient. Such antagonists may be administered in the form of compositions adapted to be delivered to the colon, such as depot formulations and suppositories. Assay methods for the development of compounds for the treatment of IBS are also provided.Type: GrantFiled: November 28, 2000Date of Patent: September 3, 2002Assignee: Pharmagene Laboratories LimitedInventors: Richard A. Borman, Nicholas S. Tilford, Gordon S. Baxter
-
Patent number: 6410340Abstract: We have identified and purified to homogeneity from lymphatic tissues a 8.4 kDa immunophilin that specifically and avidly binds the immunosuppressant drugs FK-506 (Kd=0.8 nM) and rapamycin (Kd=0.08 nM) and their pharmacologically active metabolites and derivatives, but does not bind cyclosporin A. The isolated 8.4 kDa protein appears to be identical to authentic human and bovine ubiquitins in all measured respects (partial amino acid sequence, molecular weight, binding constants, binding specificity, biochemical aspects, and utility as the protein binding reagent in binding assays for immunosuppressant drugs in fluid samples, including patient blood). The availability of commercial quantities of human recombinant ubiguitin removes a supply barrier to the use of immunophilin protein binding assays for the estimation of FK-506, rapamycin and pharmacologically active metabolites and derivatives in the clinical setting.Type: GrantFiled: August 23, 2000Date of Patent: June 25, 2002Assignee: Children's Research InstituteInventor: Steven J. Soldin
-
Patent number: 6406864Abstract: An assay method is disclosed which isolates and detects the presence of a disease related conformation of a protein (e.g., PrPSc) present in a sample also containing the non-disease related conformation of the protein (e.g., PrPC). The sample is treated (e.g., contacted with protease) in a manner which hydrolyzes the disease related conformation and not the non-disease related conformation. The treated sample is contacted with a binding partner (e.g., a labeled antibody which binds PrPSc) and the occurrence of binding provides and indication that PrPSc is present. Alternatively the PrPSc of the treated sample is denatured (e.g., contacted with guanadine) or unfolded. The unfolded PrPSC is contacted with a binding partner and the occurrence of binding indicates the presence of PrPSc in the sample.Type: GrantFiled: January 3, 2001Date of Patent: June 18, 2002Assignee: The Regents of the University of CaliforniaInventors: Stanley B. Prusiner, Jiri G. Safar
-
Patent number: 6399306Abstract: Methods of reducing blood pressure levels in hypertensive subjects through the identification of subjects with an allele and/or genotype at a gene locus that positively correlates with improved success in reducing blood pressure levels, as compared to other alleles and/or genotypes at the same gene locus, and through the engagement of these subjects in exercise training for a period of time sufficient for the reduction of the subjects' blood pressure levels.Type: GrantFiled: September 5, 2000Date of Patent: June 4, 2002Assignee: University of Maryland, College Park Office of Technology CommercializationInventors: James M. Hagberg, Robert E. Ferrell, Michael D. Brown
-
Patent number: 6391565Abstract: Growth differentiation factor-3 (GDF-3) is disclosed along with its polynucleotide sequence and amino acid sequence. Also disclosed are diagnostic and therapeutic methods of using the GDF-3 polypeptide and polynucleotide sequences.Type: GrantFiled: September 3, 1999Date of Patent: May 21, 2002Assignee: The Johns Hopkins University School of MedicineInventors: Se-Jin Lee, Alexandra C. McPherron